A phase II study of high dose epirubicin in unresectable non small cell lung cancer.

Epirubicin (EPI), a doxorubicin analogue, is reported to have equal antitumour activity with lower cardiac and systemic toxicity. Recently, the maximum tolerated dose of this drug has been revised upwards with reported increased response rates in several malignancies. We initiated a phase II study o...

Full description

Saved in:
Bibliographic Details
Main Authors: Smit, E. F., Berendsen, H. H., Piers, D. A., Smeets, J., Riva, A., Postmus, P. E.
Format: Artigo
Language:Inglês
Published: Nature Publishing Group 1992
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC1977612/
https://ncbi.nlm.nih.gov/pubmed/1313691
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items